MedTrace Logo

Osimertinib for NSCLC With Uncommon EGFR Mutations

NCT05421936 · Status: SUSPENDED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-11-22

No results posted yet for this study

Summary

This is a multi-center, retrospective study of ucEGFRmut (exon 20 insertions excluded) metastatic NSCLC osimertinib-treated as first EGFR inhibitor. RECIST and RANO-BM brain objective response rate (ORR) were evaluated by investigators. mPFS, mOS and mDOR were calculated from osimertinib initiation. Mutations found at resistance were collected.

Conditions

  • Carcinoma, Non-Small-Cell Lung
  • Genes, erbB-1

Interventions

DRUG

Osimertinib

Treatment as the first EGFR-TKI

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Sheba Medical Center

    lead OTHER_GOV

Principal Investigators

  • Jair Bar, MD-PhD · Sheba Medical Center, Ramat Gan, Israel

  • Alfredo Addeo, MD · Geneva University Hospital, Geneva, Switzerland

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-27
Primary Completion
2024-09-30
Completion
2024-09-30

Countries

  • Israel

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05421936 on ClinicalTrials.gov